Jefferies issued a Buy rating on Werewolf Therapeutics (NASDAQ:HOWL) on Tuesday, citing an attractive valuation in the cancer-focused biotech ahead of a data readout scheduled in Q4 2023 for WTX-124, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results